Dr. Dinan is a health services researcher with a focus on emerging medical technology in cancer. Dr. Dinan currently holds an AHRQ K99/R00 pathway to independence award to examine adoption of Oncotype DX molecular testing in breast cancer and has conducted work in breast and other cancers examining emerging technologies and their associated disparities in utilization, outcomes and costs. Dr. Dinan has expertise in both secondary data analysis and clinical registry methodologies. Her secondary data expertise include the SEER-Medicare linked data, Medicare claims, NIS, NCDB, as well as EHR data.
Dr. Dinan holds additional appointments at the Duke Clinical Research Institute and Duke Cancer Institute where she co-leads the Patient Experience and Survivorship Focus Area in the Cancer Control and Population Sciences Program.
Education and Training
- Ph.D., University of North Carolina at Chapel Hill, 2011
- B.S., University of Virginia, 2003